Cancer Chemotherapy and Pharmacology

, Volume 66, Issue 4, pp 643–651 | Cite as

Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea

  • Kyong Hwa Park
  • Jeong Sun Kim
  • Yong Park
  • Hee Yeon Seo
  • Young Je Park
  • In Keun Choi
  • Sang Chul Oh
  • Jae Hong Seo
  • Chul Yong Kim
  • Kwang Yoon Jung
  • Sang Won ShinEmail author
  • Yeul Hong Kim
  • Jun Suk Kim
  • Nam Joon Lee
Original Article



Concomitant approach using cisplatin and 5-fluorouracil (5-FU) has shown an excellent local control rate and significantly reduced distant metastasis in patients with locally advanced nasopharyngeal carcinoma (NPC). However, optimal schedule and dosing of chemotherapy still need to be developed to reduce distant metastasis. This retrospective study was conducted to evaluate the efficacy, toxicity, and tolerability of a concurrent chemoradiation therapy (CCRT) regimen using cisplatin and 5-FU followed by adjuvant chemotherapy (AC) in patients with locoregioanlly advanced NPC.


Forty-three NPC patients who had AJCC stage T3/T4 or N2/N3 and M0 disease were evaluated. The chemotherapy during CCRT consisted of cisplatin (75 mg/m2 on day 1) plus 5-FU (750 mg/m2/day on day 1–5), delivered every 4 weeks for two cycles. Three cycles of AC were given with cisplatin (75 mg/m2), epirubicin (37.5 mg/m2) on day 1, and bleomycin (7.5 mg/m2 bolus iv. on day 1 followed by 9 mg/m2 on day 1–5 by continuous infusion) every 3 weeks.


The overall response rate after CCRT was 95% (22 CRs and 19 PRs in 43) and 100% (16 CRs and 8 PRs in 24) after AC. Grade 3/4 neutropenia, mucositis, and weight loss were observed during CCRT phase in 18, 44, and 26% of patients, respectively. AC caused grade 3/4 neutropenia and emesis in 12.5 and 20.8% of patients, respectively.


CCRT regimen using cisplatin and 5-FU followed by three cycles of BEC chemotherapy was effective in locally advanced NPC patients, with acceptable and reversible acute toxicities.


Nasopharyngeal carcinoma Concomitant chemoradiation Adjuvant chemotherapy Retrospective analysis Korea 



This work was supported by a Korea University Grant.


  1. 1.
    Teo P, Yu P, Lee WY et al (1996) Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 36:291–304PubMedGoogle Scholar
  2. 2.
    Kwong DL, Sham JS, Au GK et al (2004) Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 22:2643–2653CrossRefPubMedGoogle Scholar
  3. 3.
    Chua DT, Sham JS, Au GK, Choy D (2002) Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis. Int J Radiat Oncol Biol Phys 53:334–343PubMedGoogle Scholar
  4. 4.
    Chan AT, Teo PM, Leung TW et al (1995) A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33:569–577PubMedGoogle Scholar
  5. 5.
    (1996) Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 35:463–469Google Scholar
  6. 6.
    Ma J, Mai HQ, Hong MH et al (2001) Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19:1350–1357PubMedGoogle Scholar
  7. 7.
    Chi KH, Chang YC, Guo WY et al (2002) A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 52:1238–1244CrossRefPubMedGoogle Scholar
  8. 8.
    Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16:1310–1317PubMedGoogle Scholar
  9. 9.
    Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1,753 patients. Int J Radiat Oncol Biol Phys 64:47–56PubMedGoogle Scholar
  10. 10.
    Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21:631–637CrossRefPubMedGoogle Scholar
  11. 11.
    Chan AT, Leung SF, Ngan RK et al (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97:536–539CrossRefPubMedGoogle Scholar
  12. 12.
    Lee AW, Lau WH, Tung SY et al (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23:6966–6975CrossRefPubMedGoogle Scholar
  13. 13.
    Hui EP, Ma BB, Leung SF et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27:242–249CrossRefPubMedGoogle Scholar
  14. 14.
    Chan AT, Felip E (2009) Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):123–125PubMedGoogle Scholar
  15. 15.
    Ma BB, Hui EP, Chan AT (2008) Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 99:1311–1318CrossRefPubMedGoogle Scholar
  16. 16.
    Bachouchi M, Cvitkovic E, Azli N et al (1990) High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst 82:616–620CrossRefPubMedGoogle Scholar
  17. 17.
    Taamma A, Fandi A, Azli N et al (1999) Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 86:1101–1108CrossRefPubMedGoogle Scholar
  18. 18.
    Boussen H, Cvitkovic E, Wendling JL et al (1991) Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol 9:1675–1681PubMedGoogle Scholar
  19. 19.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  20. 20.
    Baujat B, Audry H, Bourhis J et al (2006) Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev:CD004329Google Scholar
  21. 21.
    Chen Y, Liu MZ, Liang SB et al (2008) Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 71:1356–1364PubMedGoogle Scholar
  22. 22.
    Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23:579–589CrossRefPubMedGoogle Scholar
  23. 23.
    Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98CrossRefPubMedGoogle Scholar
  24. 24.
    Hong JP, Lee SW, Song SY et al (2009) Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies. Eur J Cancer Care 18:636–641CrossRefGoogle Scholar
  25. 25.
    Wee J, Tan EH, Tai BC et al (2005) Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23:6730–6738CrossRefPubMedGoogle Scholar
  26. 26.
    Fuwa N, Shikama N, Hayashi N et al (2007) Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil–a phase II study. Oral Oncol 43:948–955CrossRefPubMedGoogle Scholar
  27. 27.
    Azli N, Fandi A, Bachouchi M et al (1995) Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am 1:222–229PubMedGoogle Scholar
  28. 28.
    Groome PA, O’Sullivan B, Mackillop WJ et al (2006) Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 64:1002–1012PubMedGoogle Scholar
  29. 29.
    Cheng JC, Chao KS, Low D (2001) Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 96:126–131CrossRefPubMedGoogle Scholar
  30. 30.
    Lee N, Harris J, Garden AS et al (2009) Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 27:3684–3690CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Kyong Hwa Park
    • 1
  • Jeong Sun Kim
    • 1
  • Yong Park
    • 1
  • Hee Yeon Seo
    • 1
  • Young Je Park
    • 3
  • In Keun Choi
    • 1
  • Sang Chul Oh
    • 1
  • Jae Hong Seo
    • 1
  • Chul Yong Kim
    • 3
  • Kwang Yoon Jung
    • 2
  • Sang Won Shin
    • 1
    Email author
  • Yeul Hong Kim
    • 1
  • Jun Suk Kim
    • 1
  • Nam Joon Lee
    • 4
  1. 1.Division of Oncology/Hematology, Department of Internal MedicineKorea University College of MedicineSeoulKorea
  2. 2.Department of Otorhinolaryngology/Head-and-Neck SurgeryKorea University College of MedicineSeoulKorea
  3. 3.Department of Radiation OncologyKorea University College of MedicineSeoulKorea
  4. 4.Department of RadiologyKorea University College of MedicineSeoulKorea

Personalised recommendations